Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma - is it necessary? Journal Article
| Authors: | Ok, C. Y.; Ye, Q.; Li, L.; Manyam, G. C.; Deng, L.; Goswami, R. R.; Wang, X.; Montes-Moreno, S.; Visco, C.; Tzankov, A.; Dybkaer, K.; Zhang, L.; Abramson, J.; Sohani, A. R.; Chiu, A.; Orazi, A.; Zu, Y.; Bhagat, G.; Richards, K. L.; Hsi, E. D.; Choi, W. W. L.; van Krieken, J. H.; Huh, J.; Ponzoni, M.; Ferreri, A. J. M.; Zhang, S.; Parsons, B. M.; Xu, M.; Møller, M. B.; Winter, J. N.; Piris, M. A.; Xu-Monette, Z. Y.; Medeiros, L. J.; Young, K. H. |
| Article Title: | Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma - is it necessary? |
| Abstract: | Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly (EBV+ DLBCL-e) is a molecularly distinct variant of DLBCL, characterized by a monoclonal B-cell proliferation that occurs in patients >50 years of age without a history or clinicopathologic evidence of immunodeficiency. However, patients with EBV+ DLBCL younger than 50-years-old also exist in Western countries. We evaluated the clinicopathologic, immunophenotypic and genetic features in Cacausian patients with EBV+ DLBCL who are ≤50 years of age and compared this patient group to patients who are >50 years. In patients who are ≤50 years, less frequent expression of BCL6 and a trend of more frequent expression of CD30 and pSTAT3 were found in patients with EBV+ DLBCL. In patients who are >50 years, common expression of CD30, p50, pSTAT3 and less frequent expression of BCL6 were observed. Older patients also more commonly had a poor performance status (ECOG≥2). Comparing EBV+ DLBCL patients in ≤50 years versus >50 years, both groups had similar clinicopathologic, immunophenotypic and genetic features. Gene expression profiling, microRNA profiling and treatment outcome of the younger patients with EBV+ DLBCL was not distinctive from tumors in older patients. Based on our data, we suggest that the arbitrary age cutoff for EBV+ DLBCL is unnecessary and should be eliminated in the WHO lymphoma classification scheme. |
| Keywords: | adult; clinical article; controlled study; protein expression; treatment outcome; prednisone; histopathology; doxorubicin; disease classification; rituximab; genetic analysis; cell proliferation; protein bcl 2; stat3 protein; microrna; gene expression profiling; cyclophosphamide; protein p53; myc protein; immunophenotyping; world health organization; lymphoproliferative disease; protein bcl 6; large cell lymphoma; immune deficiency; elderly; epstein barr virus; caucasian; cd30 antigen; dlbcl; ebv; monoclonal b cell lymphocytosis; human; male; female; article |
| Journal Title: | Oncotarget |
| Volume: | 6 |
| Issue: | 16 |
| ISSN: | 1949-2553 |
| Publisher: | Impact Journals |
| Date Published: | 2015-06-10 |
| Start Page: | 13935 |
| End Page: | 13946 |
| Language: | English |
| PROVIDER: | scopus |
| PUBMED: | 26101854 |
| PMCID: | PMC4546442 |
| DOI: | 10.18632/oncotarget.4324 |
| DOI/URL: | |
| Notes: | Export Date: 2 July 2015 -- Source: Scopus |
